COHANCE444.00

Cohance Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEASTERDMLALPATHLABNATCOPHARMWOCKPHARMANEULANDLABNHMcap ₹16,987 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt38.678.1169.7169.7
Net Debt-782.6-199.0-145.8-145.8
Total Debt/Equity0.020.040.040.04
Net Debt/Equity-0.38-0.11-0.04-0.04
Total Debt/EBITDA0.100.210.400.40
Net Debt/EBITDA-1.93-0.53-0.34-0.34
Interest Coverage (EBIT/Interest)47.1424.116.446.44
Total Debt/Total Capital %1.854.074.044.04
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.